Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CollPlant Biotechnologies (CLGN) Common Equity (2018 - 2025)

Historic Common Equity for CollPlant Biotechnologies (CLGN) over the last 8 years, with Q3 2025 value amounting to $9.3 million.

  • CollPlant Biotechnologies' Common Equity fell 4499.94% to $9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year decrease of 4499.94%. This contributed to the annual value of $13.5 million for FY2024, which is 5248.76% down from last year.
  • As of Q3 2025, CollPlant Biotechnologies' Common Equity stood at $9.3 million, which was down 4499.94% from $12.5 million recorded in Q2 2025.
  • CollPlant Biotechnologies' Common Equity's 5-year high stood at $50.6 million during Q1 2021, with a 5-year trough of $9.3 million in Q3 2025.
  • Moreover, its 5-year median value for Common Equity was $32.3 million (2022), whereas its average is $30.6 million.
  • In the last 5 years, CollPlant Biotechnologies' Common Equity skyrocketed by 90784.01% in 2021 and then plummeted by 5248.76% in 2024.
  • Quarter analysis of 5 years shows CollPlant Biotechnologies' Common Equity stood at $45.1 million in 2021, then dropped by 28.46% to $32.3 million in 2022, then dropped by 12.21% to $28.3 million in 2023, then crashed by 52.49% to $13.5 million in 2024, then crashed by 30.89% to $9.3 million in 2025.
  • Its last three reported values are $9.3 million in Q3 2025, $12.5 million for Q2 2025, and $12.4 million during Q1 2025.